Within a blood vessel, flow exerts tangential and perpendicular forces upon endothelial cells, leading to cytoskeletal rearrangements and changes in gene expression[@R4]. While initial embryonic vascular patterning is largely independent of these hemodynamic forces, the onset of circulation drives subsequent remodeling of the circulatory system[@R4]. For example, flow plays an important role in the unilateral regression of the sixth AA during mouse development[@R1]. In zebrafish, the fifth and sixth AA arise after flow begins and form a persistent connection to the lateral dorsal aortae (LDA) that provides circulation to the trunk[@R8], [@R9]. These vessels continue to undergo angiogenesis throughout larval stages to comprise the gill vasculature[@R9]. To investigate how flow affects angiogenesis, we observed development of AA5 and 6 in zebrafish embryos by 2-photon time-lapse imaging ([Supplementary Fig. 1a-c](#SD2){ref-type="supplementary-material"}). To co-visualize endothelial cells and flow, we performed microangiography on *Tg(kdrl:egfp)^la116^* embryos, which display fluorescent green endothelial cells, using unconjugated Quantum dots (QDots). At 46 hpf, we observed AA perfusion, but no connection between the fifth and sixth AA and the LDA (data not shown and [Supplementary Fig. 1d, 46h](#SD2){ref-type="supplementary-material"}). Several hours later, the AA 5/6 connecting vessel (referred to as AA5x according to reference [@R8]) sprouted from the left and right AAs ([Supplementary Movie 1](#SD3){ref-type="supplementary-material"}). At this point, the sprouts were sufficiently lumenized to allow perfusion with Qdots ([Supplementary Fig. 1d, 53.75 magnified](#SD2){ref-type="supplementary-material"}; [Supplementary Movies 1](#SD3){ref-type="supplementary-material"} and [2](#SD6){ref-type="supplementary-material"}). However, blood cells entering from the ventral aorta (VA) became trapped in AA5 and 6 ([Supplementary Movie 3](#SD7){ref-type="supplementary-material"}). AA5x sprouts then fused with the LDA to form a patent circulatory connection ([Supplementary Fig. 1d, 59.75h](#SD2){ref-type="supplementary-material"}, [Supplementary Movie 1](#SD3){ref-type="supplementary-material"}). Subsequently, the AA5x fully lumenized and blood flow through AA5 and 6 commenced ([Supplementary Movie 4](#SD8){ref-type="supplementary-material"}). These observations indicated that the AA5x develops via concomitant angiogenesis and lumenization in the presence of flow.

To determine if flow was required for this process, we performed unilateral laser microsurgery on *Tg(kdrl:egfp)^la116^* embryos to sever the connection between the VA and AA5 and 6 prior to AA5x sprouting ([Supplementary Figs. 1e, 2a](#SD2){ref-type="supplementary-material"}). Following microsurgery at 46 hpf, we observed normal AA perfusion on the unoperated side by microangiography at 72 hpf ([Fig. 1a](#F1){ref-type="fig"}). By contrast, on the operated side (right) AA5 and 6 failed to bear flow ([Fig. 1b](#F1){ref-type="fig"}), although cranial blood vessels and the AAs appeared morphologically normal ([Fig. 1b](#F1){ref-type="fig"}; [Supplementary Figure 2b](#SD2){ref-type="supplementary-material"}). A dorsal view of the same embryo revealed that the AA5x formed on the left side of the embryo, but not on the right side where flow was blocked ([Fig. 1c](#F1){ref-type="fig"}, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). To support these results, we treated *Tg(kdrl:egfp)^la116^* embryos beginning at 46 hpf with the myosin ATPase inhibitor 2,3-butanedione 2-monoxime (BDM) or the anesthetic Tricaine methanesulfonate to arrest the heart and block circulation[@R10]. In both treatments, embryos failed to form the AA5x ([Fig. 1d, e](#F1){ref-type="fig"}; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}), although vascular morphogenesis in other anatomical locations appeared normal ([Supplementary Figure 3](#SD2){ref-type="supplementary-material"}). 2-photon time-lapse microscopy of embryos without flow suggested that a failure to initiate sprouting, rather than vessel regression, was responsible for loss of AA5x ([Supplementary Movies 5](#SD9){ref-type="supplementary-material"} and [6](#SD10){ref-type="supplementary-material"}). Time lapse analysis using *Tg(fli1a:negfp)^y7^* embryos, in which endothelial cell nuclei are labeled with Egfp, revealed decreased migratory activity of cells within the aortic arches in the absence of flow when compared to wild type ([Supplementary Movies 7](#SD11){ref-type="supplementary-material"} and [8](#SD12){ref-type="supplementary-material"}). Interestingly, embryos injected with a *gata1* Morpholino displayed normal AA5x development ([Fig 1f](#F1){ref-type="fig"}, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}), suggesting that shear stress from blood cells was dispensable for AA5x angiogenesis. Together, these results indicate that the AA5x forms via angiogenesis and that this process is dependent on flow.

Vascular endothelial growth factor (Vegf) signaling has been implicated in flow-mediated AA remodeling in mouse embryos[@R1]. Accordingly, we observed AA expression of the zebrafish Vegf receptor-2 ortholog, *kdrl*, including expression in the developing AA5x at 48 hpf ([Supplementary Fig. 4a](#SD2){ref-type="supplementary-material"}). We also observed *vegfa* expression in the developing glomerulus ([Supplementary Fig. 4b, c](#SD2){ref-type="supplementary-material"}), which is located near the branch point of the dorsal aorta and towards which the AA5x sprouts ([Supplementary Fig. 4d](#SD2){ref-type="supplementary-material"}), and in cells surrounding the AA blood vessels ([Supplementary Fig. 4e](#SD2){ref-type="supplementary-material"}). Consistent with a role for Vegf signaling during AA5x angiogenesis, embryos bearing a kinase-dead mutation in Kdrl (referred to as *kdrl^y17^*; ref [@R11]) failed to form a patent AA5x ([Fig. 1g](#F1){ref-type="fig"}; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Furthermore, treatment with the Vegf receptor inhibitor SU5416 from 46 to 65 hpf resulted in a block in AA5x formation, while DMSO had no effect ([Fig. 1h](#F1){ref-type="fig"}, i; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Similarly, partial reduction of Vegfa using a low Morpholino dose (3 ng; see reference [@R12]) blocked AA5x development ([Fig. 1j, k](#F1){ref-type="fig"}). Overall vascular morphology and circulatory function, including initial perfusion of the aortic arches, were normal following these manipulations ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}). These observations demonstrate that AA5x formation requires Vegf signaling. In other developmental settings, Notch signaling coordinates Vegf-stimulated angiogenesis[@R13], [@R14]. However, we did not detect expression of Notch signaling molecules or Notch activation in the AAs ([Supplementary Fig. 5a-c](#SD2){ref-type="supplementary-material"}) and AA5x was not affected by loss of the Notch ligand *dll4* ([Supplementary Fig 5d](#SD2){ref-type="supplementary-material"}). These results suggest that a Notch-independent mechanism is responsible for Vegf-stimulated AA5x angiogenesis.

A possible candidate gene responsible for integrating flow and Vegf signaling during AA5x formation was the zinc finger transcription factor, *klf2*, which is induced by flow in endothelial cells[@R6], [@R7]. We observed that zebrafish *klf2a* was expressed in the AA in a pattern similar to the endothelial marker, *vascular-endothelial cadherin* (*cdh5*; [Fig. 2a](#F2){ref-type="fig"}) and was expressed in the developing AA5x ([Supplementary Fig. 4f](#SD2){ref-type="supplementary-material"}). Furthermore, AA expression of *klf2a*, but not *cdh5*, was reduced in *cardiac troponin T2* (*tnnt2*)-deficient embryos, which lack circulation ([Fig. 2a](#F2){ref-type="fig"}; [Supplementary Table 2; Supplementary Fig. 6a](#SD2){ref-type="supplementary-material"}, ref [@R15]) and in embryos treated with Tricaine ([Supplementary Fig. 6b; Supplementary Table 2](#SD2){ref-type="supplementary-material"}). To determine if *klf2a* was required for AA5x angiogenesis, we utilized Morpholinos targeting either the *klf2a* exon 3 splice acceptor site ([Supplementary Fig. 7a, b](#SD2){ref-type="supplementary-material"}) or the *klf2a* start codon. Embryos injected with either Morpholino displayed normal morphology and grossly normal circulatory patterns, including perfusion of the aortic arches following angiography ([Supplementary Fig. 7c, d](#SD2){ref-type="supplementary-material"} and data not shown), consistent with recent work demonstrating relatively normal flow patterns and heart rate in *klf2a*-deficient zebrafish embryos at 48 hpf [@R16]. However, the normal transient AA circulatory block persisted in *klf2a*-deficient embryos (compare [Supplementary Movies 3](#SD7){ref-type="supplementary-material"}, [4](#SD8){ref-type="supplementary-material"}, and [9](#SD13){ref-type="supplementary-material"}), suggesting a defect in AA5x formation. Indeed, while embryos injected with control Morpholino appeared normal, *klf2a*-deficient siblings failed to develop the AA5x ([Fig. 2b](#F2){ref-type="fig"}; [Supplementary Fig. 7e, f; Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Thus, despite the presence of flow, loss of *klf2a* mimics the AA5x defect observed in embryos lacking flow or Vegf signaling.

In *Xenopus laevis* embryos, *klf2* is important for Vegf receptor-2 expression [@R17]. However, *kdrl* expression appeared normal in *klf2a*-deficient zebrafish embryos ([Supplementary Fig 6a, c](#SD2){ref-type="supplementary-material"}). Similarly, neither *kdrl* nor *vegfa* were altered in embryos lacking circulation ([Supplementary Fig. 6a, c](#SD2){ref-type="supplementary-material"}) and we did not observe consistent reduction in other known *klf2* responsive genes[@R5]-[@R7] in the absence of flow or *klf2a* ([Supplementary Fig. 6a](#SD2){ref-type="supplementary-material"}). These results raised the possibility that a post-transcriptional mechanism linked flow, *klf2a*, and Vegf signaling. A candidate for this role was the endothelial-restricted microRNA, *miR-126*[@R18], which can enhance Vegf signaling[@R19], [@R20]. While *miR-126* expression was apparent in the embryonic vasculature prior to circulation ([Supplementary Fig. 8a](#SD2){ref-type="supplementary-material"}), at later stages its expression appeared much higher in the AAs ([Fig 3a](#F3){ref-type="fig"}, [Supplementary Fig. 8a](#SD2){ref-type="supplementary-material"}). Strikingly, we found that AA *miR-126* expression was dependent on both flow and *klf2a* expression. While control embryos expressed high levels of *miR-126* within the AAs, *tnnt2*- or *klf2a*-deficient embryos did not ([Fig. 3a-c](#F3){ref-type="fig"}; [Supplementary Figs. 6a and 8b, Supplementary Table 2](#SD2){ref-type="supplementary-material"}). By contrast, expression of *cdh5* and *let-7a* was unchanged in the absence of flow or *klf2a* ([Fig. 3d-f](#F3){ref-type="fig"}, [Supplementary Fig. 8b](#SD2){ref-type="supplementary-material"}), ruling out a general defect in endothelial gene expression or microRNA processing, respectively. Tricaine treatment to block flow similarly reduced *miR-126* AA expression ([Supplementary Fig. 6b; Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Embryos injected with a Morpholino to prevent *miR-126* processing ([Supplemental Fig. 8c](#SD2){ref-type="supplementary-material"}) displayed blocked AA circulation ([Supplementary Movie 10](#SD4){ref-type="supplementary-material"}) and hemorrhage in this region by 60 hpf ([Supplementary Fig. 8d](#SD2){ref-type="supplementary-material"}). Similar to loss of *klf2a*, the AA5x did not form in *miR-126*-deficient embryos ([Fig. 3g](#F3){ref-type="fig"}; [Supplementary Table 3](#SD2){ref-type="supplementary-material"}; [Supplementary Movie 11](#SD5){ref-type="supplementary-material"}). We also observed ectopic branching of segmental vessels and abnormal patterning of cranial blood vessels in *miR-126*-deficient embryos ([Supplementary Fig. 8e](#SD2){ref-type="supplementary-material"}). These results demonstrate that AA expression of *miR-126* requires flow and *klf2a* and that *miR-126* itself is required for AA5x angiogenesis.

Our results suggested that *klf2a* acted upstream of *miR-126* to induce flow-stimulated angiogenesis. Consistent with this possibility, exogenous *klf2a* in embryos lacking blood flow restored AA *miR-126* expression ([Supplementary Fig. 9a-c](#SD2){ref-type="supplementary-material"}). To further test their genetic interaction, we co-injected *klf2a* and *miR-126* Morpholinos at suboptimal doses that individually caused no, or mild low penetrant aortic arch defects ([Fig. 3h, i](#F3){ref-type="fig"}; [Supplementary Fig. 9d,e; Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Co-injection of both Morpholinos in this case caused a drastic increase in the penetrance of AA5x defects, suggesting that *miR-126* and *klf2a* act in a common pathway ([Fig. 3j](#F3){ref-type="fig"}, [Supplementary Fig. 9e, Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Interestingly, other vascular defects observed in *miR-126*-deficient embryos were not apparent in co-injected embryos ([Supplementary Fig. 8e](#SD2){ref-type="supplementary-material"}, data not shown), suggesting a specific genetic interaction between *miR-126* and *klf2a* during AA5x development. To further confirm that *miR-126* functioned downstream of *klf2a*, we drove mosaic endothelial expression of a *miR-126*/*monomeric cherry* (*mcherry*) transgene in *klf2a*-deficient embryos using the *fli1ep* promoter fragment ([Supplementary Fig. 10a](#SD2){ref-type="supplementary-material"}; ref [@R21]). This construct drove flow-independent endothelial expression of mature *miR-126* ([Supplementary Fig. 10b, c](#SD2){ref-type="supplementary-material"} and data not shown) and led to an increased proportion of *klf2a*-deficient embryos with AA5x formation as compared to injection of *klf2a* Morpholino alone ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Rescued embryos displayed *miR-126/mcherry* transgene expression in AA5x endothelial cells, including cases of bi- and uni-lateral rescue ([Fig. 3k, l](#F3){ref-type="fig"}), while the control *fli1ep:mcherry* transgene failed to rescue ([Fig. 3m](#F3){ref-type="fig"}). These results indicate that *miR-126* acts downstream of *klf2a* to drive flow-stimulated angiogenesis.

*miR-126* promotes angiogenesis by repressing *spred1* and *pik3r2*, which normally inhibit Vegf signaling[@R19], [@R20]. Our observations suggested that in the absence of flow and *klf2a*, reduced *miR-126* expression allows upregulation of these molecules thereby preventing Vegf-induced AA5x angiogenesis. While *miR-126* can repress the zebrafish *spred1* 3'UTR, it had no effect on *pik3r2* in whole embryo miRNA sensor assays ([Supplementary Fig. 11a](#SD2){ref-type="supplementary-material"}). Using an endothelial autonomous miRNA sensor assay ([Supplementary Fig. 11b](#SD2){ref-type="supplementary-material"}), we further found that the *spred1* 3' UTR prevented expression of a *mcherry* transcript in blood vessels, while *egfp* fused to a control 3'UTR was expressed ([Fig. 4a, b](#F4){ref-type="fig"}; [Supplementary Fig. 11c](#SD2){ref-type="supplementary-material"}). By contrast, the *mcherry-spred1*-3'UTR transgene was robustly expressed in embryos lacking *miR-126*, blood flow, or *klf2a* ([Fig. 4c-h](#F4){ref-type="fig"}, [Supplementary Fig. 11c](#SD2){ref-type="supplementary-material"}). These results support a genetic pathway in which *spred1* repression is mediated by *klf2a* and *miR-126* in response to flow. Accordingly, over-expression of mRNA encoding Spred1 blocked AA5x formation ([Fig. 4i, j](#F4){ref-type="fig"}, [Supplementary Table 3](#SD2){ref-type="supplementary-material"}), while reducing Spred1 in *miR-126*-deficient embryos rescued AA5x development ([Fig. 4k, l](#F4){ref-type="fig"}, [Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Taken together, our findings support the existence of a genetic pathway in which flow induces *klf2a* and *miR-126* ([Fig. 4m](#F4){ref-type="fig"}). While our data suggest that the interaction between these genes occurs in AA endothelial cells, we cannot rule out the possibility of an indirect role for *klf2a* upstream of *miR-126*. Nevertheless, flow-stimulated *miR-126* subsequently inhibits *spred1* in endothelial cells to allow angiogenesis to proceed in response to Vegf ([Fig 4m](#F4){ref-type="fig"}). In the absence of flow, *klf2a* and *miR-126* are reduced allowing *spred1* to repress Vegf-stimulated angiogenesis. Thus, *miR-126* provides a crucial link between flow and Vegf signaling to promote angiogenesis. Importantly, flow, *klf2a*, and *miR-126* were similarly required for angiogenesis in the zebrafish-xenograft model[@R22] ([Supplementary Fig 12](#SD2){ref-type="supplementary-material"}), suggesting that this pathway may represent a general mechanism for flow-stimulated angiogenesis in the zebrafish.

The stereotyped pattern of the vertebrate circulatory system is initially established by conserved genetic pathways that act before circulation to drive endothelial differentiation and provide guidance cues. How haemodynamic forces subsequently modulate these pathways *in vivo* is largely unknown. Our current work provides new insights into how an endothelial cell\'s response to flow can be integrated with early developmental signals to drive angiogenesis in the presence of flow.

Methods summary {#S1}
===============

Zebrafish and their embryos were handled according to standard protocols[@R23] and in accordance with University of Massachusetts Medical School IACUC guidelines. For laser-assisted microsurgery, embryos at 46 hpf were anesthetized and immobilized in 0.5% of low-melt agarose (Biorad). The connection between AA5 and AA6 and the ventral aorta was ablated using a Micropoint laser (Photonic Instrument, Inc) mounted on a Zeiss AX10 Imager M1. SU5416 (Calbiochem) was prepared and used as described previously[@R11]. Control embryos were treated with 0.1% dimethyl sulfoxide (DMSO). To arrest heartbeat, embryos were treated with 15 mM of 2,3-butanedione 2-monoxime (BDM; Sigma-Aldrich) or with buffered Tricaine methanesulfonate (Sigma-Aldrich) at 0.66 mg/ml in egg water for the indicated times. Two-photon time-lapse imaging, confocal microscopy and microangiography was performed as previously[@R13], [@R24], with additional modifications as noted in Supplementary Methods. Antisense riboprobes against *dll4*, *vegfa*, *kdrl, fli1a,* and *cdh5* were generated and used for whole mount in situ hybridization as described elsewhere[@R25]. A *klf2a* fragment was PCR amplified and cloned by Gateway recombination. The resulting clone was linearized with BglII and a DIG-labeled riboprobe was synthesized using T7 polymerase. Digoxigenin (DIG)-labeled locked nucleic acid (LNA) probes (Exiqon, Copenhagen) were used to detect mature *miR-126* and *let-7* using *in situ* hybridization or Northern analysis as described elsewhere[@R18]. Morpholinos, mRNA and Tol2-based plasmids were prepared and injected as previously[@R11],[@R21]. In cases of co-injection with Morpholinos, Tol2-plasmids and transposase, a DNA/transposase mRNA mixture was initially injected, followed by Morpholino. Plasmid construction details are provided in the full methods section. Morpholinos against *vegfa*, *tnnt2* and *gata1* have been described elsewhere[@R15], [@R26], [@R25]; all other Morpholino and oligonucleotide sequences are provided in the full methods section.
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Zebrafish lines {#S3}
===============

The *Tg(kdrl:egfp)^la116^* and *kdrl^y17^* lines have been described elsewhere [@R8],[@R11]. The Notch sensor line, *Tg(tp1bglob:egfp)^um14^*, has been described and validated as Notch-responsive in previous studies [@R27]. A description of the *Tg(fli1ep:dsRedEx)^um13^* line can be found in Covassin et al [@R28] while the *Tg(fli1a:negfp)^y7^* line is described in Roman et al [@R29].

Two-photon time lapse imaging and confocal microscopy {#S4}
=====================================================

Embryos were treated with 0.003% mM 1-phenyl-2-thiourea to prevent pigmentation and immobilized using 0.1% Tricaine as elsewhere [@R13]. Microangiography was performed using Qtracker 655 non-targeted quantum dots (Invitrogen) or Rhodamine-labeled Dextran as described elsewhere [@R13]. Embryos were mounted in low-melt agarose containing PTU and Tricaine as previously[@R13]. Two-photon imaging was performed as previously [@R24], except that GFP and unconjugated Qdots (655 nm emission) were simultaneously excited at 830 nm and the emitted fluorescence separated using a two-photon specific filter cube with 510/50 nm and 645/60 nm emission bandpasses. Both the sample and the objective were kept at 28°C during the experiment. Laser scanning confocal microscopy was performed as described elsewhere [@R11]. To generate time-lapse movies and vertical projections, we utilized Imaris (Bitplane). Flash Professional 8 (Macromedia) was used to label movies.

Transgenic miRNA expression construct {#S5}
=====================================

To create a vector capable of expressing a zebrafish mature miRNA in a cell type-specific manner, we relied on multisite Gateway cloning. For the miRNA cassette, we constructed a middle entry (pME) clone containing a 753bp fragment of the zebrafish EF1alpha gene (accession number NM_131263) encompassing the TATA box, first non-coding exon 1, intron 1 and partial exon 2, 5\' of the ATG. This fragment was PCR-amplified from genomic zebrafish DNA using high fidelity DNA polymerase (forward 5\'-CGCTCGGTCCTCCTCTCGAGTATAAATTCTC-3\' and reverse 5\'-CTTTCCCATGTCGACTAAGTTTCTGCGGACC-3\'), cloned into a TOPO TA cloning vector (Invitrogen) and validated by sequencing. A multicloning site was inserted between the StuI and ClaI restriction sites of intron 1 by annealing the primers 5\'-CCTCTGTGGTACCATTCTACATGTGTTGATTTTCTGTATTTTAGTGAATTCTGT GAT-3\' and 5\'-CGATCACAGAATTCACTAAAATACAGAAAATCAACACATGTAGAATGGTACC ACAGAGG-3\' to allow insertion of a pri-miRNA with KpnI and EcoRI restriction sites. Finally, the recombinant fragment was shuttled into pDONR 221 (Invitrogen) by first amplifying the insert using the primers 5\'-GGGACAAGTTTGTACAAAAAAGCAGGCTCTCGAGTATAAATTCTCCAACCAA AGC-3\' (forward) and 5\'-GGGGACCACTTTGTACAAGAAAGCTGGGTCGATACCGTCGACTAAGTTTCTG CGGACC-3\' (reverse). The resulting PCR fragment was used in a BP reaction with pDONR221 to generate a miRNA middle entry vector (pME-miR) and confirmed by sequencing.

To generate a *miR-126* middle entry cassette, 600 bp of genomic sequence flanking the mature *miR-126* sequence on chromosome 8 (miRBase accesion number MI0001979,Zv7) was amplified by PCR (see [Table](#T1){ref-type="table"} below for primer sequences). The resulting fragment was cloned by Zero Blunt TOPO PCR Cloning (Invitrogen) and validated by sequencing. The *miR-126* fragment was subcloned using flanking EcoRI sites into pME-miR to give pME-*miR126* (see above). To generate an endothelial autonomous miRNA expression construct, we utilized multisite Gateway LR cloning. The following plasmids were included in the multisite reaction: p5E-*fli1ep*[@R28], pME-*miR*-126, p3E-*mcherry* [@R21], [@R30], and pDestTol2pA [@R30]. A control vector was constructed by using the empty pME-miR in a parallel LR multisite reaction. The reaction was performed using LR clonase II plus (Invitrogen) as previously [@R21].

miRNA sensor assays {#S6}
===================

We amplified the 3'UTR of zebrafish *spred1* or *pik3r2* by PCR and cloned them via BP Gateway recombination with pDONR P2-P3 (Invitrogen) to generate 3' entry plasmids (p3E-*spred1*-3'utr, p3E-*pik3r2*-3'utr, see [Table](#T1){ref-type="table"} below for primer sequences). For whole embryo assays, we generated a pCS2-based construct by performing multisite Gateway LR reactions with pCS2Dest2 [@R21], pENTR-*egfp* [@R21] and the p3E-*spred1*-*3'utr* or p3E-*pik3r2-3'utr* entry clones. The resulting plasmids were referred to as pCS-*egfp-spred1-3'utr* or pCS-*egfp-pik3r2-3'utr*. These plasmids were linearized by digestion with NotI and used as templates to synthesize capped mRNA using SP6 polymerase (mMessage Machine, Ambion). As a control, we synthesized mRNA encoding the monomeric red fluorescent protein, *mcherry* containing the SV40 late polyadenylation sequence found in pCS2. 60 pg of *mcherry* mRNA was co-injected with 60 pg of *egfp* sensor mRNA with or without 60 fmol of *miR-126* duplex (see below for sequences) into 1-cell stage zebrafish embryos. Embryos were observed at 24 hpf for MCherry and Egfp expression using a MZFLIII microscope equipped with epifluorescence. Digital images were captured using a Zeiss mRC digital camera and Axiovision software.

To generate an endothelial autonomous miRNA sensor construct, we cloned the basal promoter-EGFP-polyA cassette from plasmid pENTRbasEGFP [@R21] into the PspOMI site of pDest Tol2pA [@R30], in an opposite orientation to the attR4-attR3 Gateway cassette in the parent vector (see [Supplementary Figure 11b](#SD2){ref-type="supplementary-material"}); this plasmid is referred to as pTolbasPegfprev-R4R3. To generate the injection construct, we performed a multisite Gateway reaction using pTol-basPegfprev-R4R3, a 5' entry clone containing the *fli1ep* fragment (p5e-fli1ep [@R28]), a middle entry clone encoding mcherry (pME-mcherry), and p3E-*spred1*-3'utr.

For endothelial autonomous assays, we co-injected 25 pg of Tol2 *transposase* mRNA, 25 pg of Tol2-reporter plasmid, with or without *miR-126*, *tnnt2*, or *klf2a* Morpholino, as indicated. Embryos were observed for mCherry and Egfp expression using a MZFLIII microscope equipped with epifluorescence. Subsequently, confocal stacks were acquired as previously [@R28] and voxel intensity of red and green fluorescence was quantified in 3-dimensional reconstructions using Imaris.

klf2a mRNA expression construct {#S7}
===============================

We amplified the open reading frame of zebrafish *klf2a* (NM_131856) by PCR and cloned it via BP Gateway recombination with pDONR 221 to generate a middle entry (referred to as pME-*klf2a*; see [Table](#T1){ref-type="table"} below for primer sequences). In parallel, we constructed a Destination vector in which mCherry was placed upstream of the viral 2A sequence and an attB1/attB2 Gateway cassette (pCSmCherry2ADest). Transfer of an in-frame entry clone into this vector generates a cassette in which two proteins are expressed from a single transcript. To generate an injection construct, we performed a LR Gateway reaction with pCSmCherry2ADest and pME-*klf2a*. The resulting plasmid is referred to as pCS-*mcherry*-2A-*klf2a*. This plasmid was linearized by digestion with NotI and used as template to synthesize capped mRNA using SP6 polymerase (mMessage Machine, Ambion). As a control, we synthesized mRNA encoding the monomeric red fluorescent protein, *mcherry.* Wild type embryos were injected with 400 pg of mRNA into one cell stage embryos with or without *tnnt2* MO (3 ng) or *klf2a* MO splice site (2.5 ng) and control MO (3ng). We assayed for expression and presence of the injected mRNA at 48 hpf by visualization of mCherry fluorescence and RT-PCR, respectively (see [Supplementary Fig. 9a, b](#SD2){ref-type="supplementary-material"}).

Xenografts {#S8}
==========

Implantation of Ras-transformed NIH3T3 cells into zebrafish embryos was performed as previously described[@R22]. Cells were labeled with PKH26 red fluorescent linker (Sigma) and subsequently grafted into 48 hpf *Tg(kdrl:egfp)^la116^* embryos that had been injected with control (20 ng), *tnnt2* (3 ng), *klf2a* splice blocking MO (2.5 ng) or *miR-126* (20 ng) morpholino. Microangiography was performed on embryos 24 hours following the graft followed by confocal microscopy. Imaris (Biplane) software was use to measure and compare vascular tumor volume in 3-dimensional reconstructions of confocal stacks.

Quantitative RT-PCR {#S9}
===================

Total RNA was extracted from 20 to 40 embryos per group in Trizol (Invitrogen) according to the manufacturer\'s instructions. Products were amplified in a real-time PCR reaction with StepOne Plus Real-Time PCR System (Applied Biosystems) using a Power SYBR Green mix (Applied Biosystems) according to the manufacturer\'s instructions. Mature *miR-126* was amplified using the miScript Reverse Transcription Kit and miScript SYBR Green PCR Kit (Qiagen) with primers indicated below. Morpholinosequences*klf2a* ATG MOGGACCTGTCCAGTTCATCCTTCCAC*klf2a* splice blocking MOCTCGCCTATGAAAGAAGAGAGGATT*miR-126* MOTGCATTATTACTCACGGTACGAGTTTGAGTC*spred1* MOAAACCTGTGGAAGGAGAAGGAAACCcontrol MOOligo-31N*tnnt2* MOCATGTTTGCTCTGATCTGACACGCAPrimersKlf2a attb1gggg aca agt ttg tacaaaaaagcaggctacaggtcc ATGCATCTCAGCKlf2a attb2GGGGACCACTTTGTACAAGAAAGCTGGGTcattttccagagtccgttcCSpred 3′UTR attb2GGGG ACA GCT TTC TTG TAC AAA GTG GCGCTTGTGCCACCGCTGCSpred 3′UTR attb3GGGG AC AAC TTTGTATAATAA AGT TGGCAGAGCGTTTGGCGGTGTPIk3r2 3UTR attb2GGGG ACA GCT TTC TTG TAC AAA GTG GCACAACGACTCGCTGAATGTPIK3r2 3UTR attb3GGGG AC AAC TTT GTA TAA TAA AGT TGTCCTCAAGCTGGGATCATGTSpred ORF attb1ggggacaagtttgtacaaaaaagcaggctacatgagcgaa gaa cca aacSpred ORF attb2ggggaccactttgtacaagaaagctgggttcatcctgcagccttgtmiR126 chm8 FTGCCATGCCTTGACGAGAAGmiR126 chm8 RGTGATATTTAATGTAACATGCCqpcr Bact FAGCTTGAAACTCGCCAAGTGqpcr Bact RCAGCTTTATAGCCGGCACTGqpcr vegf FGCCAAAGGCAGAAGTCAAAGqpcr vegf RTGCAGGAGCATTTACAGGTGqpcr Kdrl FTCTACTGGGCTTTTCCCTCTCqpcr Kdrl RAGGGTTACTATGGTGACGTTGCqpcr Zelastin FGCTCGTCTCCATACAAAGCAqpcr Zelastin RCAGAACTCCTCCTGGTAGCCqpcr Z Tie2 FGCCGTCAAGAGGATGAAAGAqpcr Z Tie2 RGCTGCTGTGAGGAGAGTGTGqpcr Znos1 FTCAAATACGCCACCAACAAAqpcr Znos1 RGAGAAGAAGGGGCAAAACATCqpcr ZItgb5 FTGGGAAGGATGGACAAAGAGqpcr ZItgb5 RCGGGTGAATGAGGAGACACTqpcr ZEdg1 FCCACCGTATTCAGCGTTATTqpcr ZEdg1 RGTCAAGGAGGAGCAGGATGAqpcr ZEdn 1 FATGAGGCGAAACCACAGAAGqpcr ZEdn 1 RAGAAACCACTTGAGCGAGGF-qpcr klf2aCCAACGCCAACCAAAGAGTAR-qpcr klf2aCTCGCCTGTGTGTGTTCTGTMir 126 qpcr F for miRscriptCGT ACC GTG AGT AAT AAT GCR-RT-PCR klf2aACGTGGTACCCGCACGGCGAACTCACACTTGF-RT-PCR klf2aACGTGGTACCacgcacggcgactcacacttgmiRNA DuplexmiR-126 senseucguaccgugaguaauaaugcmiR-126 antisensegcauuauuacucacgguacgamiR-126 scramble antisensegcaccacaacucaagguucga

![AA5x angiogenesis requires flow and Vegf signaling\
**a-k,***Tg(kdrl:egfp)^la116^* embryos at 72 hpf (**a-c**), 60 hpf (**d-f**) or 65 hpf (**g-k**). **a-c**, **g-k** Embryos subjected to microangiography. Endothelial cells are green, flow is red. **a, b,** Lateral views, anterior to left (**a**), or right (**b**), dorsal is up. **c-k**, dorsal view, anterior is up. **a, b**, aortic arches (AA, numbered, indicated by arrows) after severing right AA5 and 6 from ventral aorta; opa -- opercular artery. **c,** dorsal view of embryo in **a**, **b**. **d, e,** Stills from [Supplementary Movies 5](#SD9){ref-type="supplementary-material"} and [6](#SD10){ref-type="supplementary-material"}. Embryos treated beginning at 46 hpf with BDM (**d**), Tricaine (**e**), or injected with *gata1* MO (**f**). **g**, *kdrl^y17^* mutant embryo at 65 hpf. **h-k**, Embryos treated with 2.5 μM SU5416 (**h**) or 0.1% DMSO (**i**) beginning at 46 hpf or injected with 3 ng of scrambled MO (**j**) or 3 ng of Vegfa MO (**k**). **c-k**, Arrows: lateral dorsal aortae (LDA), arrowheads: AA5x.](nihms-178415-f0001){#F1}

![AA5x angiogenesis requires *klf2a*\
**a**, Embryos subjected to whole mount *in situ* hybridization at 65 hpf using indicated riboprobes (*klf2a*, *cdh5*). Lateral view, anterior to the left, dorsal is up. Embryos were injected with 2 ng of scrambled control (*left*) or *tnnt2* (*right*) MO. Aortic arch region is denoted by black boxes; aortic arches 4-6 are indicated by numbered arrows in cases where staining is present. **b**, Microangiogram of 72 hpf *Tg(kdrl:egfp)^la116^* embryo injected with 11 ng-embryo scrambled control MO (*top*) or *klf2a* ATG MO (*bottom*); arrowheads indicate position of normal AA5x formation, arrows denote lateral dorsal aortae. Dorsal views, anterior is up.](nihms-178415-f0002){#F2}

![*miR-126* acts downstream of *klf2a* during AA5x development\
**a-f,** Ventral view, anterior is up. Bracket: AA3-6. Expression of *miR-126* (**a-c**) or *cdh5* (**d-f**). Embryos injected with 11 ng control MO (**a, d**), 2 ng *tnnt2* MO (**b, e**), 11 ng *klf2a* ATG MO (**c, f**). **g-j,***Tg(kdrl:egfp)^la116^* embryos at 65 hpf, dorsal view, anterior is up. Endothelial cells are green, blood flow is red. Embryos injected with 20 ng of control or *miR-126* MO (**g**), 2 ng *klf2a* ATG MO (**h**), 7 ng *miR-126* MO (**i**), or co-injected with 2 ng *klf2a* ATG MO and 7 ng *miR-126* MO (**j**). **k**-**m**, *Tg(kdrl:egfp)^la116^* embryos co-injected with 11 ng *klf2a* ATG MO and pTol-*fli1ep:miR-126/mcherry* (k, l) or 11 ng *klf2a* ATG MO and pTol-*fli1ep:mcherry* (**m**). **k-m**, Yellow indicates *egfp* and *mcherry* co-expression; dorsal views, anterior is up. **g-m,** Arrows: lateral dorsal aortae (LDA), arrowheads: AA5x.](nihms-178415-f0003){#F3}

![Flow-mediated repression of Spred1 is required for AA5x angiogenesis\
**a-h,** Cranial vessel expression of a *miR-126* sensor at 65 hpf; lateral views, anterior to the left, dorsal is up. **a, c, e, g,** Expression of Egfp fused to control 3'UTR (green) and mCherry-*spred1*-3'UTR (red), coexpression is yellow. **b, d, f, h,** Expression of mCherry-*spred1*-3'UTR (red). Embryos co-injected with *miR-126* sensor construct and 20 ng control MO (**a, b**), 20 ng *miR-126* MO (**c, d**), 2 ng *tnnt2* MO (**e, f**) , or 11 ng *klf2a* ATG MO (**g, h**). **i-l,***Tg(kdrl:egfp)^la116^* embryos at 65 hpf, dorsal view, anterior is up. Endothelial cells in green, circulation in red. Arrow - Lateral dorsal aortae; AA5x - arrowheads. Embryos left uninjected (**i**), injected with 100 pg *spred1* mRNA (**j**), 20 ng control MO (**k**), or 1 ng *spred1* MO and 20 ng *miR-126* MO (**l**). **m**, Pathway responsible for flow-stimulated angiogenesis.](nihms-178415-f0004){#F4}
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